106 related articles for article (PubMed ID: 26547551)
21. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
22. Flavonol Biosynthesis Genes and Their Use in Engineering the Plant Antidiabetic Metabolite Montbretin A.
Irmisch S; Ruebsam H; Jancsik S; Man Saint Yuen M; Madilao LL; Bohlmann J
Plant Physiol; 2019 Jul; 180(3):1277-1290. PubMed ID: 31004005
[TBL] [Abstract][Full Text] [Related]
23. Discovery of UDP-Glycosyltransferases and BAHD-Acyltransferases Involved in the Biosynthesis of the Antidiabetic Plant Metabolite Montbretin A.
Irmisch S; Jo S; Roach CR; Jancsik S; Man Saint Yuen M; Madilao LL; O'Neil-Johnson M; Williams R; Withers SG; Bohlmann J
Plant Cell; 2018 Aug; 30(8):1864-1886. PubMed ID: 29967287
[TBL] [Abstract][Full Text] [Related]
24. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
Bischoff H
Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
[TBL] [Abstract][Full Text] [Related]
25. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment.
Pickavance L; Widdowson PS; King P; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Oct; 125(4):767-70. PubMed ID: 9831913
[TBL] [Abstract][Full Text] [Related]
26. Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-d-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy.
Hotta N; Koh N; Sakakibara F; Naruse K; Yamada T; Takeuchi N; Yamada K; Fukasawa H; Kakuta H
Biomed Pharmacother; 1996; 50(6-7):297-302. PubMed ID: 8952871
[TBL] [Abstract][Full Text] [Related]
27. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
28. Insulin binding and glucose transport in adipocytes of acarbose-treated Zucker lean and obese rats.
Vasselli JR; Flory T; Fried SK
Int J Obes; 1987; 11 Suppl 3():71-5. PubMed ID: 3326849
[TBL] [Abstract][Full Text] [Related]
29. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
Robertson J; Nelson R; Kass P; Neal L
Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
[TBL] [Abstract][Full Text] [Related]
30. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology of alpha-glucosidase inhibition.
Bischoff H
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():3-10. PubMed ID: 8001624
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
Scheen AJ
Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
[TBL] [Abstract][Full Text] [Related]
33. Recurrent intermittent restraint delays fed and fasting hyperglycemia and improves glucose return to baseline levels during glucose tolerance tests in the Zucker diabetic fatty rat--role of food intake and corticosterone.
Bates HE; Kiraly MA; Yue JT; Goche Montes D; Elliott ME; Riddell MC; Matthews SG; Vranic M
Metabolism; 2007 Aug; 56(8):1065-75. PubMed ID: 17618951
[TBL] [Abstract][Full Text] [Related]
34. Effective control of glycemic status and toxicity in Zucker diabetic fatty rats with an orally administered vanadate compound.
Clark TA; Edel AL; Heyliger CE; Pierce GN
Can J Physiol Pharmacol; 2004 Oct; 82(10):888-94. PubMed ID: 15573149
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
[TBL] [Abstract][Full Text] [Related]
36. Metabolic effects of acarbose administration in normal and diabetic rats.
Haugaard N; Hess ME; Locke CL; Torbati A; Wildey G
Biochem Pharmacol; 1984 May; 33(9):1503-8. PubMed ID: 6732866
[TBL] [Abstract][Full Text] [Related]
37. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose.
Rösen P; Osmers A
Horm Metab Res; 2006 Sep; 38(9):575-86. PubMed ID: 16981139
[TBL] [Abstract][Full Text] [Related]
38. Antidiabetic and antioxidant effects of Annona muricata (Annonaceae), aqueous extract on streptozotocin-induced diabetic rats.
Florence NT; Benoit MZ; Jonas K; Alexandra T; Désiré DD; Pierre K; Théophile D
J Ethnopharmacol; 2014 Feb; 151(2):784-90. PubMed ID: 24076471
[TBL] [Abstract][Full Text] [Related]
39. Studies on the glycemic and lipidemic effect of Murraya koenigii in experimental animals.
Kesari AN; Kesari S; Singh SK; Gupta RK; Watal G
J Ethnopharmacol; 2007 Jun; 112(2):305-11. PubMed ID: 17467937
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
